Department of Gastrointestinal Surgery, Peking University People's Hospital, 11 Xizhimen Nan Street, Xicheng District, Beijing, 100044, P. R. China.
BMC Gastroenterol. 2023 Jun 3;23(1):192. doi: 10.1186/s12876-023-02770-y.
The clinicopathological features, surgical outcomes, and long-term survival of patients with young-onset colon cancer (≤ 40 years old) remain controversial.
The clinicopathologic and follow-up data of patients aged < 40 years with colon cancer between January 2014 and January 2022 were reviewed. The primary objectives were clinical features and surgical outcomes. Long-term survival was investigated as a secondary objective.
Seventy patients were included in the study, and no significant rising trend (Z=0, P=1) of these patients was observed over the 8-year study period. Stage IV disease was accompanied by more ulcerative or infiltrating type (84.2% vs. 52.9%, P=0.017) and lymphovascular or perineural invasion (64.7% vs. 25.5%, P=0.003) than stage I-III disease. After a median follow-up time of 41 months (range 8-99 months), the 1-, 3-, and 5-year estimated overall survival (OS) rates were 92.6%, 79.5%, and 76.4%, respectively. The 1-, 3-, and 5-year progression-free survival (PFS) rates were 79.6%, 71.7%, and 71.7%, respectively. Multivariate Cox regression showed that M+ stage (hazard ratio [HR], 3.942; 95% confidence interval [CI], 1.176-13.220, P=0.026) was the only independent risk factor affecting OS. Meanwhile, tumor deposits (HR, 4.807; 95% CI, 1.942-15.488, P=0.009), poor differentiation (HR, 2.925; 95% CI, 1.012-8.454, P=0.047), and M+ stage (HR, 3.540; 95% CI, 1.118-11.202, P=0.032) independently affected PFS.
The differences in the clinical features, surgical outcomes, and long-term survival between young adults and elderly colon cancer patients need further investigation.
青年发病结肠癌(≤40 岁)的临床病理特征、手术结果和长期生存情况仍存在争议。
回顾 2014 年 1 月至 2022 年 1 月期间年龄<40 岁的结肠癌患者的临床病理和随访资料。主要研究目的为临床特征和手术结果。次要研究目的为长期生存情况。
共纳入 70 例患者,在 8 年的研究期间,未观察到这些患者数量的显著上升趋势(Z=0,P=1)。与Ⅰ-Ⅲ期疾病相比,Ⅳ期疾病伴有更多的溃疡性或浸润性类型(84.2% vs. 52.9%,P=0.017)和淋巴管或神经周围侵犯(64.7% vs. 25.5%,P=0.003)。中位随访时间为 41 个月(8-99 个月)后,估计的 1、3 和 5 年总生存(OS)率分别为 92.6%、79.5%和 76.4%。1、3 和 5 年无进展生存(PFS)率分别为 79.6%、71.7%和 71.7%。多变量 Cox 回归显示,M+期(危险比[HR],3.942;95%置信区间[CI],1.176-13.220,P=0.026)是唯一影响 OS 的独立危险因素。同时,肿瘤沉积物(HR,4.807;95%CI,1.942-15.488,P=0.009)、低分化(HR,2.925;95%CI,1.012-8.454,P=0.047)和 M+期(HR,3.540;95%CI,1.118-11.202,P=0.032)独立影响 PFS。
青年和老年结肠癌患者的临床特征、手术结果和长期生存情况存在差异,需要进一步研究。